Study guide
11.4 Infection Imaging Procedures
Certified Nuclear Medicine Technologist CNMT
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current CNMT Exam Facts 1.2 How to Use This Guide
2 Radiation Physics Fundamentals
2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles
3 Biological Effects & ALARA
3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring
4 NRC & Regulatory Compliance
4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records
5 Generators & Kit Preparation
5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control
6 Tc-99m Diagnostic Agents
6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells
7 Non-Tc Diagnostic & PET Agents
7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents
8 Therapeutics, Adjuncts & Administration
8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents
9 Non-Imaging Instrumentation
9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment
10 Imaging Systems & Quality Control
10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization
11 Pulmonary, Bone, Oncology & Infection Imaging
11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures
12 Renal, Endocrine & Hematopoietic Imaging
12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique
13 Cardiovascular Procedures
13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing
14 GI, CNS, Therapy & Hybrid CT Procedures
14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency
15 Patient Care & Clinical Workflow
15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis
11.4 Infection Imaging Procedures
Key Takeaways Explain This Topic AI
Ga-67 citrate images infection/inflammation (and some tumors) with multi-day imaging; bowel and normal lacrimal/marrow activity are pitfalls
Labeled WBC imaging uses In-111 oxine or Tc-99m HMPAO; choose based on chronicity, anatomy (abdomen vs extremities), and logistics
In-111 WBC: dual photopeaks (~171/245 keV), imaging typically at 4 and 24 hours (sometimes 48 h); low normal GI activity early—better for abdominal infection
Tc-99m HMPAO WBC: 140 keV, higher counts, earlier imaging (often 0.5–4 h, sometimes delayed); biliary/bowel excretion can confound abdominal reads
Indications include osteomyelitis, IBD, and fever of unknown origin; antibiotics, chronic vs acute processes, and wrong-patient labeling are critical pitfalls
Last updated: August 2026
11.4 Infection Imaging Procedures
Quick Answer: Ga-67 for infection/inflammation (multi-day). Labeled WBCs — In-111 oxine vs Tc-99m HMPAO —for osteomyelitis , IBD , FUO . Know imaging times , normal distribution , and pitfalls ( antibiotics , chronic vs acute, labeling ID).
Ga-67 for Infection
Ga-67 citrate localizes in inflammatory and infected tissue via transferrin/lactoferrin pathways and leukocyte-related mechanisms (teaching level). It remains useful when labeled WBC imaging is impractical (leukopenia, some spinal infections historically) or when protocol prefers Ga-67.
- Item Teaching notes
- Activity Often ~5 mCi class IV (range ~3–6+ mCi per protocol)
- Collimator / energies Medium energy; multiple photopeaks
- Imaging Frequently 24–72 h (infection protocols may image earlier and later)
- Normal activity Liver, spleen, marrow, bowel, salivary/lacrimal, nasopharynx, genitalia
- Strengths Chronic infection, some opportunistic infections, discitis/osteomyelitis problem cases
- Weaknesses Slow, bowel confusion, less specific; largely superseded by WBC/MRI/PET in many pathways
Tech tips: schedule multi-day returns; consider bowel prep if ordered; use SPECT/CT for spine and complex sites; document recent surgery (wound uptake).
Labeled White Blood Cell Imaging
Autologous leukocytes are separated, labeled, and reinjected so they migrate to sites of active infection/inflammation . Labeling technique (Domain III) must be flawless; procedure-day focus is indication, timing, biodistribution, and pitfalls .
In-111 Oxine WBCs vs Tc-99m HMPAO WBCs
- Feature In-111 oxine WBC Tc-99m HMPAO WBC
- Label In-111 oxine Tc-99m exametazime (HMPAO)
- Half-life / energy t½ 2.8 d; ~171 & 245 keV t½ 6 h; 140 keV
- Typical adult activity ~0.3–0.5 mCi class ~5–10+ mCi class
- Usual imaging times ~4 h and 24 h (± 48 h) ~30 min–4 h ; optional later
Normal distribution Spleen > liver > marrow; minimal early bowel/urinary Spleen, liver, marrow; renal, bladder, biliary → bowel with time
Abdomen/pelvis infection Often preferred (less physiologic GI activity early) GI excretion can mimic or mask IBD/abscess
- Extremities / osteomyelitis Excellent delayed imaging Excellent counts and resolution early
- Same-day convenience Multi-day Better same-day logistics
Both require same-patient reinjection only , aseptic handling, and assay of labeling efficiency per SOP.
Indications
Indication How WBC imaging helps
Osteomyelitis (appendicular skeleton, complicated hardware) Focal WBC uptake with complementary bone marrow (sulfur colloid) imaging to separate marrow expansion from infection
- Inflammatory bowel disease Active bowel segments accumulate labeled WBCs (In-111 often preferred for abdomen)
- Fever of unknown origin / occult infection Survey for abscess or focal pyogenic infection
- Vascular graft / soft-tissue infection Focal uptake along graft or collection
- Prosthetic joint infection workups Part of multi-modality algorithms
Bone marrow pairing: In the axial skeleton and around prostheses, Tc-99m sulfur colloid marrow scan plus WBC scan distinguishes discordant infection (WBC+/marrow−) from congruent marrow packing.
Imaging Workflow (Tech)
Confirm CBC/WBC count adequacy for labeling; verify two patient identifiers on blood and dose.
Coordinate pharmacy/lab pickup and reinjection timing—cell viability falls with delay.
Inject labeled cells IV; flush well; never administer through filters that trap cells unless protocol says otherwise.
Image at protocol times with correct collimator (ME for In-111; LEHR for Tc-99m).
Include whole-body or limited FOV as ordered; add SPECT/CT for complex anatomy.
For osteomyelitis near marrow-rich bone, schedule/compare marrow imaging when ordered.
Normal Distribution Differences — Exam Favorites
- Observation Likely explanation
- Hot spleen on both agents Normal (splenic sequestration of cells)
- Early renal/bladder on HMPAO-WBC Expected secondary excretion pathway
- Progressive bowel on delayed HMPAO-WBC Physiologic biliary/GI excretion —not automatically IBD
Focal bowel on In-111 WBC at 24 h without migration pattern control Suspect true inflammation—physician interprets
- Lung uptake early after reinjection Can reflect cell activation/damage during labeling
- Pitfalls
- Antibiotics
Ongoing antibiotic therapy may decrease sensitivity by reducing leukocyte recruitment and organism load. Document antibiotic type and duration; do not cancel unilaterally—flag for the interpreting physician. Some protocols prefer imaging before prolonged therapy when clinically safe.
Chronic vs Acute Infection
Labeled WBCs excel in acute pyogenic processes rich in neutrophils. Chronic low-grade infection, some fungal/TB processes, and vertebral osteomyelitis may be falsely negative or better suited to MRI, Ga-67, or FDG depending on pathway. Exam stems that stress “chronic nonpyogenic” often point away from classic WBC positivity.
Other Traps
- Pitfall Result
- Wrong-patient cells Never-event hemolytic/infectious risk—hard stop
- Delayed reinjection Poor viability → low sensitivity, abnormal lung uptake
- Recent surgery Nonspecific wound uptake
- Steroids / immunosuppression Altered migration
- Ignoring marrow expansion False + osteomyelitis near prosthesis without colloid comparison
- Reading HMPAO bowel as abscess without timing False positive abdomen
- Quick Selection Guide
- Clinical scenario Often preferred infection tracer (teaching)
- Abdominal abscess / IBD In-111 WBC
- Extremity osteomyelitis, need high resolution same day Tc-99m HMPAO WBC
- Leukopenic patient / selected chronic or spinal cases Ga-67 (or other modality per protocol)
- FUO survey WBC or Ga-67 per institutional pathway
Master In-111 vs HMPAO biodistribution and timing , plus antibiotic and chronic-disease sensitivity limits —those distinctions dominate CNMT infection procedure items.
Scheduling Notes for the Technologist
Infection studies are multi-step: blood draw, labeling time, reinjection, and delayed imaging returns. Explain the full timeline at booking so patients do not leave after injection thinking the study is finished. Coordinate Ga-67 multi-day visits and WBC same-day vs next-day imaging with staffing and camera energy windows. Always reconcile the ordered indication with the agent on hand before venipuncture—switching from HMPAO-WBC to In-111 mid-workup requires a new labeling plan, not a simple window change.